TY - JOUR T1 - Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases JF - BJGP Open JO - BJGP Open DO - 10.3399/BJGPO.2021.0083 VL - 5 IS - 6 SP - BJGPO.2021.0083 AU - Toby Peter Speirs AU - Nicole Tuffin AU - Finlay Mundy-Baird AU - Helena Sakota AU - Sarah Mulholland AU - Michelle Westlake AU - Max Lyon AU - Andrew R Medford AU - Charles Sharp AU - Michael Darby AU - Mahableshwar Albur AU - Francis Keeley AU - Helena Burden AU - Charlie Kenward AU - Elizabeth Jonas AU - Shaney Barratt AU - Huzaifa I Adamali Y1 - 2021/01/01 UR - http://bjgpopen.org/content/5/6/BJGPO.2021.0083.abstract N2 - Background Long-term nitrofurantoin (NF) treatment can result in pulmonary and hepatic injury. Current guidelines do not outline the type or frequency of monitoring required for detection of these injuries.Aim To assess 1) awareness of NF complications among prescribers; 2) monitoring practice; and 3) to describe the pulmonary sequelae of NF-related complications.Design & setting Evaluation of prescribing habits by questionnaires and review of GP databases, and case-note review in secondary care.Method The following study procedures were undertaken: 1) an electronic questionnaire was distributed to prescribers, interrogating prescribing and monitoring practices, and awareness of complications; 2) an analysis was undertaken (June–July 2020) of NF monitoring among GPs in the local clinical commissioning group (CCG); and 3) a case review was carried out of patients diagnosed with NF-induced interstitial lung disease (NFILD) at the interstitial lung disease (ILD) centre (2014–2020).Results A total of 125 prescribers of long-term NF responded to the questionnaire (82.4% GPs; 12.0% urologists). Many were unaware of the potential for liver (42.4%) and lung (28.0%) complications; 40.8% and 52.8% never monitored for these, respectively. Only 53.3% of urologists believed themselves responsible for arranging monitoring, while nearly all GPs believed this to be the prescriber’s responsibility (94.2%). One-third of all responders considered current British National Formulary (BNF) guidelines 'not at all sufficient/clear', with mean clarity scoring of 2.2/5. Among patients with NFILD (n = 46), NF had been prescribed most often (69.6%) for treatment of recurrent UTI and 58.6% (n = 27) were prescribed for >6 months. On withdrawal of the medication 61.4% displayed resolution (completely or minimal fibrosis), while 15.9% of patients had progressive lung fibrosis.Conclusion NF can cause marked or irreversible lung complications and there is currently a shortfall in awareness and monitoring. Existing monitoring guidelines should be augmented. ER -